Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NMT1 | P30419 | 9/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361237 | 0.82 | ALDH1A1 (0.52) | SMN1; SMN2LMNANMT1MAPTNPSR1 | |
| SCHEMBL5470492 | 0.76 | USP10 (0.46) | SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL5466315 | 0.74 | LMNA (0.44) | SMN1; SMN2LMNACNR1CNR2MAPT | |
| SCHEMBL5327097 | 0.72 | PDE10A (0.49) | SMN1; SMN2CNR1CNR2MAPTMAPK1 | |
| SCHEMBL5355725 | 0.69 | PDE4A (0.42) | SMN1; SMN2CNR1CNR2NPC1RAB9A | |
| SCHEMBL5356153 | 0.68 | TP53 (0.44) | SMN1; SMN2LMNACNR1CNR2MAPT | |
| SCHEMBL5459372 | 0.67 | ALDH1A1 (0.43) | SMN1; SMN2LMNANPC1 | |
| SCHEMBL5353454 | 0.67 | KMT2A (0.52) | SMN1; SMN2LMNAMAPTNPSR1MAPK1 | |
| SCHEMBL5370074 | 0.67 | TP53 (0.45) | SMN1; SMN2LMNACNR1CNR2MAPT | |
| SCHEMBL5777096 | 0.63 | NPC1 (0.46) | SMN1; SMN2CNR1CNR2NPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287699-A1 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287699-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SMN1; SMN2 2454/4885LMNA 4460/4885NMT1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.